Mesothelioma drug trial stopped early – did it work?

NCT ID NCT02863055

First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 26 times

Summary

This study tested whether the drug nintedanib could help people with a rare lung cancer called malignant pleural mesothelioma. Patients who had stable disease or improvement after initial chemotherapy were given either nintedanib or a placebo to see if it delayed cancer growth. The trial was stopped early after enrolling only 37 people, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL MESOTHELIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Manchester University NHS Foundation Trust - UHSM-Wythenshawe Hospital

    Wythenshawe, Manchester, M23 9LT, United Kingdom

  • NHS South Tyneside-South Tyneside District Hospital

    South Shields, United Kingdom

  • Ospedale San Paolo

    Milan, Italy

  • Royal Marsden Hospital

    Chelsea, United Kingdom

  • Royal Marsden Hospital

    Sutton, United Kingdom

  • Royal Marsden Hospital - Kingston

    Kingston, United Kingdom

  • Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital

    Sheffield, United Kingdom

  • UZ Antwerpen

    Antwerp, Belgium

  • UZ Gent

    Ghent, Belgium

Conditions

Explore the condition pages connected to this study.